Latest News

  • 21st September 2020

    Arecor to present at EASD 2020 – oral presentation of phase I clinical trial of AT247, a novel Ultra Rapid Acting Insulin

  • 25th June 2020

    Arecor featured in New Scientist’s Business and Industry 2020 Life Sciences campaign – bringing effective and affordable drugs to market more quickly

  • 15th June 2020

    Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin


  • 13/12/2018

    Arecor to attend the 37th annual J.P. Morgan healthcare conference

  • 29/10/2018

    Press Release – Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage

  • 15/10/2018

    Press release – Arecor joins ELITE Investor Roadshow to China

  • 10/09/2018

    Press Release – Arecor secures £6m investment for the clinical development of its diabetes speciality pharma portfolio

  • 08/08/2018

    Press Release – Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018, Sheraton Boston, Boston, MA, USA

  • 02/07/2018

    Patent portfolio update – Arecor successfully defends a key European polysaccharide vaccine patent in its opposition proceedings

  • 21/06/2018

    Press release – Arecor announces Superfast Insulin data presentations at the American Diabetes Association 78th Scientific Sessions

  • 19/06/2018

    Press release – US$1.3 million grant awarded to Arecor & Manchester Institute of Biotechnology

  • 10/05/2018

    Arecor to present at the World Congress’ Biologics Formulation and Drug Delivery Technologies Summit 2018 in Boston, MA, USA

  • 10/01/2018

    Arecor Ltd is pleased to announce the launch of its new website at:

  • 08/01/2018

    European patent for Arecor’s proprietary technology enabling highly concentrated biotherapeutics

  • 04/01/2018

    Arecor and JDRF announce successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes